Facts, values, and attention-deficit hyperactivity disorder (ADHD): an update on the controversies
- PMID: 19152690
- PMCID: PMC2637252
- DOI: 10.1186/1753-2000-3-1
Facts, values, and attention-deficit hyperactivity disorder (ADHD): an update on the controversies
Abstract
The Hastings Center, a bioethics research institute, is holding a series of 5 workshops to examine the controversies surrounding the use of medication to treat emotional and behavioral disturbances in children. These workshops bring together clinicians, researchers, scholars, and advocates with diverse perspectives and from diverse fields. Our first commentary in CAPMH, which grew out of our first workshop, explained our method and explored the controversies in general. This commentary, which grows out of our second workshop, explains why informed people can disagree about ADHD diagnosis and treatment. Based on what workshop participants said and our understanding of the literature, we make 8 points. (1) The ADHD label is based on the interpretation of a heterogeneous set of symptoms that cause impairment. (2) Because symptoms and impairments are dimensional, there is an inevitable "zone of ambiguity," which reasonable people will interpret differently. (3) Many other variables, from different systems and tools of diagnosis to different parenting styles and expectations, also help explain why behaviors associated with ADHD can be interpreted differently. (4) Because people hold competing views about the proper goals of psychiatry and parenting, some people will be more, and others less, concerned about treating children in the zone of ambiguity. (5) To recognize that nature has written no bright line between impaired and unimpaired children, and that it is the responsibility of humans to choose who should receive a diagnosis, does not diminish the significance of ADHD. (6) Once ADHD is diagnosed, the facts surrounding the most effective treatment are complicated and incomplete; contrary to some popular wisdom, behavioral treatments, alone or in combination with low doses of medication, can be effective in the long-term reduction of core ADHD symptoms and at improving many aspects of overall functioning. (7) Especially when a child occupies the zone of ambiguity, different people will emphasize different values embedded in the pharmacological and behavioral approaches. (8) Truly informed decision-making requires that parents (and to the extent they are able, children) have some sense of the complicated and incomplete facts regarding the diagnosis and treatment of ADHD.
Similar articles
-
Acute Effects of Parent Stimulant Medication Versus Behavioral Parent Training on Mothers' ADHD, Parenting Behavior, and At-Risk Children.J Clin Psychiatry. 2020 Sep 8;81(5):19m13173. doi: 10.4088/JCP.19m13173. J Clin Psychiatry. 2020. PMID: 32926603 Clinical Trial.
-
Pilot Medical Certification.2023 Feb 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2023 Feb 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 33620822 Free Books & Documents.
-
Diagnosis and treatment of attention deficit hyperactivity disorder (ADHD).NIH Consens Statement. 1998 Nov 16-18;16(2):1-37. NIH Consens Statement. 1998. PMID: 10868163 Review.
-
Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.Pediatrics. 2004 Nov;114(5):e541-7. doi: 10.1542/peds.2004-0844. Pediatrics. 2004. PMID: 15520087
-
[Hearing impairment and psychopathological disorders in children and adolescents. Review of the recent literature].Encephale. 2003 Jul-Aug;29(4 Pt 1):329-37. Encephale. 2003. PMID: 14615703 Review. French.
Cited by
-
Controversies concerning the diagnosis and treatment of bipolar disorder in children.Child Adolesc Psychiatry Ment Health. 2010 Mar 10;4:9. doi: 10.1186/1753-2000-4-9. Child Adolesc Psychiatry Ment Health. 2010. PMID: 20219111 Free PMC article.
-
Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate.Eur Child Adolesc Psychiatry. 2016 Feb;25(2):141-9. doi: 10.1007/s00787-015-0718-0. Epub 2015 May 22. Eur Child Adolesc Psychiatry. 2016. PMID: 25999292 Free PMC article. Clinical Trial.
-
Health-related quality of life and functional outcomes from a randomized-withdrawal study of long-term lisdexamfetamine dimesylate treatment in children and adolescents with attention-deficit/hyperactivity disorder.CNS Drugs. 2014 Dec;28(12):1191-203. doi: 10.1007/s40263-014-0193-z. CNS Drugs. 2014. PMID: 25139785 Free PMC article. Clinical Trial.
-
Willingness to use ADHD treatments: a mixed methods study of perceptions by adolescents, parents, health professionals and teachers.Soc Sci Med. 2012 Jan;74(1):92-100. doi: 10.1016/j.socscimed.2011.10.009. Epub 2011 Nov 17. Soc Sci Med. 2012. PMID: 22133584 Free PMC article.
-
[Attention deficit/hyperactivity disorder in childhood and adolescence: from the social construct to pharmacological Calvinism].Aten Primaria. 2012 Mar;44(3):125-7. doi: 10.1016/j.aprim.2011.10.007. Epub 2012 Jan 3. Aten Primaria. 2012. PMID: 22221964 Free PMC article. Spanish. No abstract available.
References
-
- Pastor PN, Reuben CA. Vital Health Stat. Vol. 10. National Center for Health Statistics; 2008. Diagnosed Attention Deficit Hyperactivity Disorder and Learning Disability: United States, 2004–2005. - PubMed
-
- Safer DJ, Zito JM, Fine EM. Increased methylphenidate usage for attention deficit disorder in the 1990s. Pediatrics. 1996;98:1084–1088. - PubMed
-
- Schwabe U, Paffrath D. Arzneiverordnungs-Report 2006. Berlin: Springer; 2006.
Grants and funding
LinkOut - more resources
Full Text Sources